Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

2.

Lee

DW

,

Santomasso

BD

,

Locke

FL

, et al.

ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

.

Biol Blood Marrow Transplant

.

2019

;

25

:

625

-

638

.

doi:10.1016/j.bbmt.2018.12.758

.

3.

Hines

MR

,

Knight

TE

,

McNerney

KO

, et al.

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome

.

Transplant Cell Ther

.

2023

;

29

(

7

):

438.e1

-

438.e16

.

doi:10.1016/j.jtct.2023.03.006

.

4.

Shalabi

H

,

Gust

J

,

Taraseviciute

A

, et al.

Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells

.

Nat Rev Clin Oncol

.

2021

;

18

(

6

):

363

-

378

.

doi:10.1038/s41571-020-00456-y

.

5.

Rejeski

K

,

Greco

R

,

Onida

F

, et al.

An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA

.

HemaSphere

.

2023

;

7

(

5

):

e889

.

doi:10.1097/hs9.0000000000000889

.

6.

Juluri

KR

,

Wu

QV

,

Voutsinas

J

, et al.

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

.

Blood Adv

.

2022

;

6

(

7

):

2055

-

2068

.

doi:10.1182/bloodadvances.2020004142

.

7.

Chakraborty

R

,

Hill

BT

,

Majeed

A

,

Majhail

NS

.

Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies

.

Transplant Cell Ther

.

2021

;

27

(

3

):

222

-

229

.

doi:10.1016/j.jtct.2020.10.002

.

8.

Rejeski

K

,

Perez

A

,

Sesques

P

, et al.

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

.

Blood

.

2021

;

138

(

24

):

2499

-

2513

.

doi:10.1182/blood.2020010543

.

9.

Levine

JE

,

Grupp

SA

,

Pulsipher

MA

, et al.

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

.

J Immunother Cancer

.

2021

;

9

(

8

):

e002287

.

doi:10.1136/jitc-2020-002287

.

10.

Fried

S

,

Avigdor

A

,

Bielorai

B

, et al.

Early and late hematologic toxicity following CD19 CAR-T cells

.

Bone Marrow Transplant

.

2019

;

54

:

1643

-

1650

.

doi:10.1038/s41409-019-0487-3

.

11.

Jain

T

,

Olson

TS

,

Locke

FL

.

How I treat cytopenias after CAR T-cell therapy

.

Blood

.

2023

;

141

(

20

):

2460

-

2469

.

doi:10.1182/blood.2022017415

.

12.

Santomasso

BD

,

Nastoupil

LJ

,

Adkins

S

, et al.

Management of immune- related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline

.

J Clin Oncol

.

2021

;

39

(

35

):

3978

-

3992

.

doi:10.1200/JCO.21.01992

.

13.

Lipsitt

A

,

Beattie

L

,

Harstead

E

, et al.

Allogeneic CD34(+) selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection

.

Pediatr Blood Cancer

.

2023

;

70

(

3

):

e30166

.

doi:10.1002/pbc.30166

.

14.

Mullanfiroze

K

,

Lazareva

A

,

Chu

J

, et al.

CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy

.

Blood Adv

.

2022

;

6

(

16

):

4715

-

4718

.

doi:10.1182/bloodadvances.2022007572

.

15.

Deya-Martinez

A

,

Alonso-Saladrigues

A

,

Garcia

AP

, et al.

Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia

.

Bone Marrow Transplant

.

2021

;

56

(

2

):

376

-

386

.

doi:10.1038/s41409-020-01027-6

.

16.

Kampouri

E

,

Walti

CS

,

Gauthier

J

,

Hill

JA

.

Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians

.

Expert Rev Hematol

.

2022

;

15

(

4

):

305

-

320

.

doi:10.1080/17474086.2022.2063833

.

17.

Hill

JA

,

Krantz

EM

,

Hay

KA

, et al.

Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy

.

Blood Adv

.

2019

;

3

(

22

):

3590

-

3601

.

doi:10.1182/bloodadvances.2019000717

.

18.

Wudhikarn

K

,

Perales

M-A

.

Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy

.

Bone Marrow Transplant

.

2022

;

57

(

10

):

1477

-

1488

.

doi:10.1038/s41409-022-01756-w

.

19.

Hill

JA

,

Seo

SK

.

How I prevent infections in patients receiving CD19- targeted chimeric antigen receptor T cells for B-cell malignancies

.

Blood

.

2020

;

136

(

8

):

925

-

935

.

doi:10.1182/blood.2019004000

.

20.

Arnold

DE

,

Maude

SL

,

Callahan

CA

,

DiNofia

AM

,

Grupp

SA

,

Heimall

JR

.

Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients

.

Pediatr Blood Cancer

.

2020

;

67

(

3

):

e28092

.

doi:10.1002/pbc.28092

.

21.

Cordeiro

A

,

Bezerra

ED

,

Hirayama

AV

, et al.

Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells

.

Biol Blood Marrow Transplant

.

2020

;

26

(

1

):

26

-

33

.

doi:10.1016/j.bbmt.2019.08.003

.

22.

Jarisch

A

,

Wiercinska

E

,

Huenecke

S

, et al.

Immune responses to SARS-CoV-2 vaccination in young patients with anti-CD19 chimeric antigen receptor T cell-induced B cell aplasia

.

Transplant Cell Ther

.

2022

;

28

(

7

):

366.e1

-

366.e7

.

doi:10.1016/j.jtct.2022.04.017

.

23.

Gust

J

,

Finney

OC

,

Li

D

, et al.

Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy

.

Ann Neurol

.

2019

;

86

(

1

):

42

-

54

.

doi:10.1002/ana.25502

.

24.

Gofshteyn

JS

,

Shaw

PA

,

Teachey

DT

, et al.

Neurotoxicity after CTL019 in a pediatric and young adult cohort: neurotoxicity after CTL019

.

Ann Neurol

.

2018

;

84

(

4

):

537

-

546

.

doi:10.13039/100000065

.

25.

Shalabi

H

,

Wolters

PL

,

Martin

S

, et al.

Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy

.

J Immunother

.

2018

;

41

(

7

):

350

-

358

.

doi:10.1097/cji.0000000000000241

.

26.

Laetsch

TW

,

Myers

GD

,

Baruchel

A

, et al.

Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial

.

Lancet Oncol

.

2019

;

20

(

12

):

1710

-

1718

.

doi:10.1016/S1470-2045(19)30493-0

.

27.

Ruark

J

,

Mullane

E

,

Cleary

N

, et al.

Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy

.

Biol Blood Marrow Transplant

.

2020

;

26

(

1

):

34

-

43

.

doi:10.13039/100000062

.

28.

Hoogland

AI

,

Barata

A

,

Logue

J

, et al.

Change in neurocognitive performance among patients with non-hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy

.

Transplant Cell Ther

.

2022

;

28

(

6

):

305.e1

-

305.e9

.

doi:10.1016/j.jtct.2022.03.023

.

29.

Cheung

YT

,

Sabin

ND

,

Reddick

WE

, et al.

Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis

.

Lancet Haematol

.

2016

;

3

(

10

):

e456

-

e466

.

doi:10.13039/100000025

.

30.

Hanna

KS

,

Kaur

H

,

Alazzeh

MS

, et al.

Cardiotoxicity associated with chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies: a systematic review

.

Cureus

.

2022

;

14

(

8

):

e28162

.

doi:10.7759/cureus.28162

.

31.

Shalabi

H

,

Sachdev

V

,

Kulshreshtha

A

, et al.

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies

.

J Immunother Cancer

.

2020

;

8

(

2

):

e001159

.

doi:10.1136/jitc-2020-001159

.

32.

Holland

EM

,

Yates

B

,

Ling

A

, et al.

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy

.

Blood Adv

.

2022

;

6

(

7

):

2167

-

2182

.

doi:10.1182/bloodadvances.2021006035

.

33.

Liu

H

,

Ma

Y

,

Yang

C

, et al.

Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer

.

Clin Transl Immunology

.

2020

;

9

(

10

):

e1154

.

doi:10.1002/cti2.1154

.

34.

Khanna

S

,

Mackin

AG

,

Dao

DT

, et al.

Exudative retinal detachment following chimeric antigen receptor T-cell therapy in relapsed B-cell acute lymphoblastic leukemia

.

Ophthalmic Surg Lasers Imaging Retina

.

2022

;

53

(

2

):

113

-

115

.

doi:10.3928/23258160-20220124-01

.

35.

Mumtaz

AA

,

Fischer

A

,

Lutfi

F

, et al.

Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review

.

Br J Ophthalmol

.

2023

;

107

(

7

):

901

-

905

.

doi:10.1136/bjophthalmol-2021-320814

.

36.

Mahdi

J

,

Dietrich

J

,

Straathof

K

, et al.

Tumor inflammation-associated neurotoxicity

.

Nat Med

.

2023

;

29

(

4

):

803

-

810

.

doi:10.1038/s41591-023-02276-w

.

37.

Laetsch

TW

,

Maude

SL

,

Rives

S

, et al.

Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial

.

J Clin Oncol

.

2023

;

41

(

9

):

1664

-

1669

.

doi:10.1200/JCO.22.00642

.

38.

Summers

C

,

Wu

QV

,

Annesley

C

, et al.

Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage

.

Transplant Cell Ther

.

2022

;

28

(

1

):

21

-

29

.

doi:10.1016/j.jtct.2021.10.003

.

39.

Shah

NN

,

Lee

DW

,

Yates

B

, et al.

Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

.

J Clin Oncol

.

2021

;

39

:

1650

-

1659

.

doi:10.1200/JCO.20.02262

.

40.

Cappell

KM

,

Kochenderfer

JN

.

Long-term outcomes following CAR T cell therapy: what we know so far

.

Nat Rev Clin Oncol

.

2023

;

20

(

6

):

359

-

371

.

doi:10.1038/s41571-023-00754-1

.

41.

Myers

RM

,

Shah

NN

,

Pulsipher

MA

.

How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL

.

Blood

.

2023

;

141

(

11

):

1251

-

1264

.

doi:10.1182/blood.2022016937

.

42.

Qayed

M

,

Bleakley

M

,

Shah

NN

.

Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia

.

Curr Opin Hematol

.

2021

;

28

(

6

):

373

-

379

.

doi:10.1097/moh.0000000000000685

.

43.

Bhatia

S

,

Armenian

SH

,

Landier

W.

How I monitor long-term and late effects after blood or marrow transplantation

.

Blood

.

2017

;

130

(

11

):

1302

-

1314

.

doi:10.1182/blood-2017-03-725671

.

44.

Dixon

SB

,

Chen

Y

,

Yasui

Y

, et al.

Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study

.

J Clin Oncol

.

2020

;

38

(

29

):

3418

-

3429

.

doi:10.1200/JCO.20.00493

.

45.

Krull

KR

.

Risk factors and screening for neurocognitive impacts of therapy

.

Hematology

.

2022

;

2022

(

1

):

259

-

265

.

doi:10.1182/hematology.2022000409

.

46.

Cheung

YT

,

Brinkman

TM

,

Mulrooney

DA

, et al.

Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia: sleep and cognition in childhood ALL

.

Cancer

.

2017

;

123

(

17

):

3410

-

3419

.

doi:10.13039/100000019

.

47.

Myers

RM

,

Devine

K

,

Li

Y

, et al.

Outcomes after reinfusion of CD19-specific chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia

.

Blood

.

2021

;

138

:

474

.

doi:10.1182/blood-2021-147299

.

48.

Holland

EM

,

Molina

JC

,

Dede

K

, et al.

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation

.

J Immunother Cancer

.

2022

;

10

(

5

):

e004483

.

doi:10.1136/jitc-2021-004483

.

49.

Holland

EM

,

Yates

B

,

Silbert

SK

, et al.

CAR T-cells effective for post-CART relapse: a new treatment paradigm

.

J Clin Oncol

.

2022

;

40

(

16_suppl

):

e19508

.

doi:10.13039/100000002

.

50.

Cornetta

K

,

Yao

J

,

House

K

, et al.

Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: no evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials

.

Mol Ther

.

2023

;

31

(

3

):

801

-

809

.

doi:10.1016/j.ymthe.2022.12.006

.

51.

Cornetta

K

,

Duffy

L

,

Turtle

CJ

, et al.

Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products

.

Mol Ther

.

2018

;

26

(

1

):

280

-

288

.

doi:10.13039/100000050

.

52.

Bishop

DC

,

Clancy

LE

,

Simms

R

, et al.

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells

.

Blood

.

2021

;

138

(

16

):

1504

-

1509

.

doi:10.1182/blood.2021010813

.

53.

Hsieh

EM

,

Myers

RM

,

Yates

B

, et al.

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

.

Blood Adv

.

2022

;

6

(

17

):

5222

-

5226

.

doi:10.1182/bloodadvances.2022008093

.

54.

Steffin

DHM

,

Muhsen

IN

,

Hill

LC

, et al.

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

.

Blood

.

2022

;

140

(

1

):

16

-

24

.

doi: 10.1182/blood.2022015728

.

55.

Lamble

AJ

,

Myers

RM

,

Taraseviciute

A

, et al.

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

.

Blood Adv

.

2023

;

7

(

4

):

575

-

585

.

doi:10.1182/bloodadvances.2022007423

.

56.

Mulder

RL

,

Font-Gonzalez

A

,

Green

DM

, et al.

Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International fects of Childhood Cancer Guideline Harmonization Group

.

Lancet Oncol

. (

2021

);

22

(

2

):

e57

-

e67

.

doi: 10.1016/S1470-2045(20)30582-9

.

57.

Mulder

RL

,

Font-Gonzalez

A

,

Hudson

MM

, et al.

Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group

.

Lancet Oncol

.

2021

;

22

:

e45

-

e56

.

doi: 10.1016/S1470-2045(20)30594-5

.

58.

Zver

T

,

Frontczak

S

,

Poirot

C

, et al.

Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients

.

J Ovarian Res

.

2022

;

15

(

1

):

9

.

doi: 10.1186/s13048-021-00936-4

.

59.

Socie

G

,

Salooja

N

,

Cohen

A

, et al.

Nonmalignant late effects after allogeneic stem cell transplantation

.

Blood

.

2003

;

101

(

9

):

3373

-

3385

.

doi:10.1182/blood-2002-07-2231

.

60.

Panasiuk

A

,

Nussey

S

,

Veys

P

, et al.

Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan

.

Br J Haematol

.

2015

;

170

(

5

):

719

-

726

.

doi:10.13039/501100005297

.

61.

Pfitzer

C

,

Orawa

H

,

Balcerek

M

, et al.

Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study

.

J Cancer Res Clin Oncol

.

2015

;

141

(

1

):

135

-

142

.

doi:10.1007/s00432-014-1781-5

.

62.

Ligon

JA

,

Fry

A

,

Maher

JY

, et al.

Fertility and CAR T-cells: current practice and future directions

.

Transplant Cell Ther

.

2022

;

28

(

9

):

605.e1

-

605605.e8

.

doi:10.1016/j.jtct.2022.06.002

.